#FoundationOne
Heading to Seattle? Join our workshops on 11/11 or schedule a meeting to connect with our experts & explore how we can support your team. www.foundationmedicine.com/event/join-f... #AMP2026

*FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.
Join Foundation Medicine at AMP 2026
Foundation Medicine is proud to participate in the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo. We hope you can join us for our corporate workshops and visit us at Booth #1701...
www.foundationmedicine.com
November 5, 2026 at 5:01 PM
We are proud to be a The Scientist's Top Innovations award recipient in Healthcare and Diagnostics for FoundationOne®MRD! This award honors cutting-edge technology shaping the future of life science, biotechnology and healthcare.
October 23, 2026 at 11:02 AM
An extended analysis of the TRACER study showcased the value of early detection of breast cancer recurrence & long-term disease monitoring utilizing FoundationOne®MRD.

*FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.
October 7, 2026 at 1:39 PM
コンパニオン診断、FoundationOneでやれるし希少腫瘍(小児は結構こちらに当てはまる)なら保険適応のはず…って思って調べたら「標準治療がない」「がんゲノム医療中核/拠点/連携病院である」っていう条件もあった

県内の病院を確認したら、しっかり腫瘍見てる病院は大体入ってた よかった
September 26, 2026 at 4:57 AM
【神経膠腫のトボラフェニブ、CDxが国内で承認】
中外製薬のFoundationOne CDx。BRAF V600変異またはBRAF融合遺伝子が陽性の、再発または進行性の低悪性度神経膠腫で、トボラフェニブ(オジェンダ、Ipsen)の適応判定を補助する。薬そのものの新規承認ではなく、コンパニオン診断の承認である。
中外製薬、FoundationOne CDx を神経膠腫のコンパニオン診断に承認取得──BRAF V600変異・融合遺伝子陽性例でトボラフェニブの適応判定補助へ
stellanews.life/medicaldevic...
中外製薬、FoundationOne CDx を神経膠腫のコンパニオン診断に承認取得──BRAF V600変異・融合遺伝子陽性例でトボラフェニブの適応判定補助へ
中外製薬は、FoundationOne CDx がんゲノムプロファイルについて、BRAF V600変異及びBRAF融合遺伝子陽性の神経膠腫に対するトボラフェニブのコンパニオン診断として2026年6月17日に厚生労働省の承認を取得したと発表した。対応するがん種は9種に拡大した。
stellanews.life
September 20, 2026 at 5:51 AM
👉 FoundationOne®CDx provides an accurate assessment of ERBB2 copy number status and may be a cost-effective option in patients with metastatic cancer for whom #NGS testing is recommended.
Read more about this study at the link
journals.sagepub.com/share/UCJJ4G...

#CanSky
November 21, 2025 at 11:00 AM
#ArticleinPress: FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity. Authors from the @broadinstitute.org

#OpenAccess text: www.jmdjournal.org/article/S152...
FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity
Accurate detection of EBV in tumors is essential for refining diagnosis and guiding management of EBV-associated cancers. This validation study evaluated the performance of the FoundationOne CDx (F1CD...
www.jmdjournal.org
July 29, 2025 at 6:16 PM
Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer
scientiasalut.gencat.cat
October 29, 2025 at 8:30 AM
Clinical Validity of FoundationOne Liquid CDx for Detection of BRAF V600E in Colorectal Cancer aacrjournals.org/cancerrescom... #hvhebron #onco [Text complet]
Clinical Validity of FoundationOne Liquid CDx for Detection of BRAF V600E in Colorectal Cancer
Abstract. BACKGROUND: The BRAF inhibitor encorafenib plus the anti-EGFR antibody cetuximab improved overall survival, objective response rate, and progression-free survival in previously treated BRAF ...
aacrjournals.org
August 27, 2025 at 10:15 AM
RRIDs were included in this None paper. Thanks for making your methods matter! #reproducibility #accelerateopenscience #OpenScience
Clinical Validity of FoundationOne Liquid CDx for Detection of BRAF V600E in Colorectal Cancer
doi.org
September 12, 2025 at 7:00 AM
FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics http://investors.foundationmedicine.com/releasedetail.cfm?ReleaseID=1050380
April 4, 2025 at 9:09 PM
as well as FoundationOne Heme for hematological malignancies.
www.genomeweb.com/cancer/found...
Foundation Medicine Nabs Five-Year VA Contract for Tumor Molecular Profiling of Cancer Patients
The national contract covers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.
www.genomeweb.com
September 26, 2024 at 3:51 PM
Foundation Medicine signs Five-Year Veterans Affairs contract to provide tumor molecular tests to veterans with cancer.
FM will use FoundationOne CDx and liquid-based FoundationOne Liquid CDx test as well as tissue-based FoudationOne RNA assays,
September 26, 2024 at 3:51 PM